Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been given a consensus rating of “Hold” by the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $108.18.
A number of research firms have weighed in on HALO. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Monday. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Leerink Partners lowered Halozyme Therapeutics from an “outperform” rating to a “hold” rating and lifted their price target for the company from $110.00 to $117.00 in a research report on Friday, November 6th. Morgan Stanley lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $105.00 to $109.00 in a research report on Wednesday, November 11th. Finally, Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 7th.
Check Out Our Latest Stock Report on Halozyme Therapeutics
Insider Buying and Selling at Halozyme Therapeutics
Institutional Investors Weigh In On Halozyme Therapeutics
Several hedge funds have recently bought and sold shares of the business. Thoroughbred Financial Services LLC increased its position in Halozyme Therapeutics by 0.4% during the 3rd quarter. Thoroughbred Financial Services LLC now owns 22,336 shares of the biopharmaceutical company’s stock valued at $2,465,000 after buying an additional 100 shares in the last quarter. Mather Group LLC. raised its stake in Halozyme Therapeutics by 48.9% in the third quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 136 shares during the last quarter. North Dakota State Investment Board boosted its holdings in Halozyme Therapeutics by 4.3% in the third quarter. North Dakota State Investment Board now owns 3,598 shares of the biopharmaceutical company’s stock worth $397,000 after acquiring an additional 147 shares in the last quarter. CoreCap Advisors LLC boosted its holdings in Halozyme Therapeutics by 98.0% in the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 150 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC boosted its holdings in Halozyme Therapeutics by 3.5% in the third quarter. Fifth Third Wealth Advisors LLC now owns 4,515 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 151 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.
Halozyme Therapeutics Price Performance
Shares of NASDAQ HALO opened at $95.80 on Thursday. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $134.00. The company has a debt-to-equity ratio of 13.50, a current ratio of 3.88 and a quick ratio of 3.60. The company’s 50-day moving average is $113.81 and its 200 day moving average is $85.87. The stock has a market capitalization of $10.92 billion, a P/E ratio of 24.38, a P/E/G ratio of 0.36 and a beta of 0.92.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The company had revenue of $492.97 million during the quarter, compared to the consensus estimate of $491.63 million. During the same period in the prior year, the firm earned $1.72 earnings per share. Halozyme Therapeutics’s revenue was up 39.1% on a year-over-year basis. On average, sell-side analysts expect that Halozyme Therapeutics will post 8.34 earnings per share for the current year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
Recommended Stories
- Five stocks we like better than Halozyme Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
